crashbashgame| Microchip Biology: Application for Phase III clinical trial of cidabenide for the treatment of colorectal cancer accepted

Securities Times e Company Newscrashbashgame, Microchip Biotech (688321) announced on the evening of May 12 that the company recently received a certificate from the Center for Drug Evaluation of the State Food and Drug AdministrationcrashbashgameThe "Acceptance Notice" for the registration clinical trial of domestically produced drugs, a randomized, open-label, controlled, multi-center, Phase III clinical trial of cidabenamide combined with sintilumab and bevacizumab for the treatment of advanced microsatellite stabilization or complete mismatch repair (MSS/pMMR) colorectal cancer that failed ≥2 lines of standard treatment was accepted by the Center for Drug Evaluation of the State Food and Drug Administration.

Tags:

Prev: arcadepad| ST China Railway's "shell protection" is urgent
Next: dailyspinandcoins| On May 13, 2024, the daily limit was known: the seven major benefits are expected to ferment